- Lewis Chodosh, University of Pennsylvania
Curigliano and colleagues review recent evidence demonstrating that the immune system plays a critical role in breast cancer diagnosis, and discuss future strategies of immunotherapy in breast cancer treatment.
Andre and colleagues highlight the importance of integrating biologic and clinical data for the clinical development of mTOR inhibitors in breast cancer treatment, reviewing results from randomized trials and strategies for biomarker development.
Palmitoylation of adhesion protein CD44 and consequent lipid raft affiliation inversely regulate breast cancer cell migration, and may act as a new therapeutic target in breast cancer metastasis.
Breast cancer risk may be related to the timing of different stages of puberty, and breast duct development may be a time of heightened susceptibility to carcinogenesis.
Rosen and Roarty review the paracrine signalling mechanisms involved in both normal mammary gland development and breast cancer, discussing emerging concepts in intratumoral heterogeneity and new therapeutic approaches.
Sherene Loi and colleagues review the preclinical and clinical data associated with PIK3CA mutations to understand the functional and clinical relevance of PIK3CA mutations in breast cancer, and their potential implications.
Volume 15 Suppl 1 (8 November 2013)
Liverpool, UK. 10-12 November 2013
Aims & scope
Breast Cancer Research is an international, peer-reviewed online journal, publishing original research, reviews, editorials and reports. Research articles of exceptional interest are published in all areas of biology and medicine relevant to breast cancer, including normal mammary gland biology, with special emphasis on the genetic, biochemical, and cellular basis of breast cancer. In addition, the journal publishes clinical studies with a biological basis, including Phase I and Phase II trials.
All reviews, commentaries and reports published in Breast Cancer Research become free to access 6 months after publication. See below for the latest free review.
Justin M Balko, Thomas P Stricker, Carlos L ArteagaBreast Cancer Research 2013, 15:209
(31 July 2013)
- 03 March 2014
- Personalized treatment approach may be best for second-most common breast cancer subtype
- 19 February 2014
- Targeting stem cells in triple-negative breast cancer